

## References

### I-9019

1. Zolgensma prescribing information. AveXis, Inc. May 2019.
2. Al-Zaidy S, Pickard AS, Kotha K, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. *Pediatric Pulmonology* 2019;54:179-185.
3. Mendell JR, Al-Zaidy S, Shell R, et al. Single-Dose Gene Replacement Therapy for Spinal Muscular Atrophy. *N Engl J Med* 2017;377:1713-22
4. Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy – a literature review. *Orphanet J Rare Dis.* 2017;12(1):124
5. Calucho M, Bernal S, Alias L, et al. Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. *Neuromuscul Disord.* 2018;28(3):208-215.
6. Bernal S, Alias L, Barcelo MJ, et al. The c.859G>C variant in the SMN2 gene is associated with both type II and III SMA and originates from a common ancestor. *Journal of Medical Genetics*, BMJ Publishing Group, 2010, 47 (9) pp. 640.
7. Mendell, JR, Kaspar BK, Burghes A. Phase I Gene transfer clinical trial for spinal muscular atrophy type 1 delivering the survival motor neuron gene by self complimentary AAV9. Phase I Clinical Study Protocol, Version 1.0, October 5, 2012.
8. Arnold WA, Kassar D, Kissel JT. Spinal Muscular Atrophy: Diagnosis and Management in a New Therapeutic Era. *Muscle Nerve* 2015 Feb; 51(2): 157-167. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293319/> Accessed 10/12/2020.
9. Fang P, Li L, Zeng J, et al. Molecular Characterization and Copy Number of SMN1, SMN2 and NAIP in Chinese Patients with Spinal Muscular Atrophy and Unrelated Healthy Controls. *B<C Musculoskelet Disord.* 2015; 16(1):11. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328246/> Accessed 10/2/2020.